The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer

Erkılınç, Selçuk; Taylan, Enes; Gülseren, Varol; Erkılınç, Gamze; Karadeniz, Tugba; Bağci, Mustafa; Temel, Orhan; Solmaz, Ulaş; Gökçü, Mehmet; Şancı, Muzaffer

doi:10.1097/igc.0000000000001137

Cited by 16 publications

(15 citation statements)

References 22 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with the current opinion that adenomyosis-associated endometrial cancer has a more favorable prognosis and might be a result of early diagnosis, due to the prominent symptoms of the two diseases (Habiba et al, 2018). On the other hand, the above-mentioned finding supports the idea, proposed by other authors (Koshiyama et al, 2004; Musa et al, 2012; Matsuo et al, 2014; Erkilinç et al, 2018), that adenomyosis can play a significant role as a prognostic factor in endometrial cancer, through its protective barrier effect to myometrial invasion of the tumor. Furthermore, our study included all histological subtypes, increasing the accuracy of our results, which was also suggested by Erkilinc S. et al (2018).…”

Section: Discussionsupporting

confidence: 89%

“…On the other hand, the above-mentioned finding supports the idea, proposed by other authors (Koshiyama et al, 2004; Musa et al, 2012; Matsuo et al, 2014; Erkilinç et al, 2018), that adenomyosis can play a significant role as a prognostic factor in endometrial cancer, through its protective barrier effect to myometrial invasion of the tumor. Furthermore, our study included all histological subtypes, increasing the accuracy of our results, which was also suggested by Erkilinc S. et al (2018). However, these results remain controversial, because other authors found adenomyosis as a risk factor for myometrial invasion and hence for worse prognosis ( Ismiil et al, 2007; Taneichi et al, 2014; Aydin et al, 2018).…”

Section: Discussionsupporting

confidence: 89%

“…The mean age of the patients with concurrent endometrial cancer and adenomyosis was approximately 63 years old and the majority of them were postmenopausal. This finding is in accordance with the fact that endometrial cancer appears in the later life stages, but not with the fact that adenomyosis is a disease appearing earlier in reproductive age (Erkilinç et al, 2018). Also, the mean age reported in our study is higher from what the other authors found (Mao et al, 2017; Aydin et al, 2018; Erkilinç et al, 2018).…”

Section: Discussionsupporting

confidence: 77%

See 2 more Smart Citations

EP663 Correlation between adenomyosis and endometrial cancer: 6-year experience of a single center

Zouzoulas

Tsolakidis

Efstratiou

et al. 2019

ePoster

View full text Add to dashboard Cite

Introduction Adenomyosis often co-exists in the pathological specimens after surgery for endometrial cancer. The aim of this study is to describe the clinicopathological and oncological characteristics of these patients and further investigate the possibility of malignant transformation in the adenomyotic tissue. Methods We retrospectively reviewed the medical records of all patients that underwent hysterectomy for endometrial cancer (January 2012 – December 2017). The pathological reports were studied and when adenomyosis was present, the pathological slides were reviewed in order to discover any malignant change in the adenomyotic tissue. The clinicopathological characteristics and oncological results were described. Results Out of 229 cases of endometrial cancer, 64 (28%) patients had concurrently endometrial cancer and adenomyosis. Among these 64 patients, 7 (11%) had malignant transformation of adenomyosis. The mean age of patients suffering from both endometrial cancer and adenomyosis was 63.2 years old and 57 (89%) of these patients, had early endometrial cancer. Concerning the patients with malignant transformation of adenomyosis, their mean age was 65 years old with no premenopausal case. Discussion Adenomyosis has been described in the last decades, but its malignant transformation into endometrial cancer is not fully undercovered. Further investigation is needed in order to clarify the pathologic progression of adenomyotic lesions to endometrial cancer.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

EP663 Correlation between adenomyosis and endometrial cancer: 6-year experience of a single center

Zouzoulas

Tsolakidis

Efstratiou

et al. 2019

ePoster

View full text Add to dashboard Cite

show abstract

“…We excluded 1501 studies after duplicates removal, 883 after title screening, and 14 after abstracts screening. Finally, 8 studies remained after whole study assessment [ 11 , 12 , 20 , 21 , 22 , 23 , 24 , 25 ]. The study by Erkilinc et al was excluded from the quantitative analysis because they randomly selected patients based on International Federation of Gynecology and Obstetrics (FIGO) grade of EC [ 11 ].…”

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics of Patients with Endometrial Cancer and Adenomyosis

Casadio

Raffone

Maletta

et al. 2021

Cancers

View full text Add to dashboard Cite

A better endometrial cancer (EC) prognosis in patients with coexistent adenomyosis has been reported. Unfortunately, it is still unclear if this better prognosis is related to a more favorable clinical profile of adenomyosis patients. We aimed to evaluate differences in the clinical profiles of EC patients with and without adenomyosis. A systematic review and meta-analysis was performed by searching seven electronics databases for all studies that allowed extraction of data about clinical characteristics in EC patients with and without adenomyosis. Clinical characteristics assessed were: age, Body Mass Index (BMI), premenopausal status, and nulliparity. Mean difference in mean ± standard deviation (SD) or odds ratio (OR) for clinical characteristics between EC patients with and without adenomyosis were calculated for each included study and as a pooled estimate, and graphically reported on forest plots with a 95% confidence interval (CI). The Z test was used for assessing the overall effect by considering a p value < 0.05 as significant. Overall, eight studies with 5681 patients were included in the qualitative analysis, and seven studies with 4366 patients in the quantitative analysis. Pooled mean difference in mean ± SD between EC women with and without adenomyosis was −1.19 (95% CI: −3.18 to 0.80; p = 0.24) for age, and 0.23 (95% CI: −0.62 to 1.07; p = 0.60) for BMI. When compared to EC women without adenomyosis, EC women with adenomyosis showed a pooled OR of 1.53 (95% CI: 0.92 to 2.54; p = 0.10) for premenopausal status, and of 0.60 (95% CI: 0.41 to 0.87; p = 0.007) for nulliparity. In conclusion, there are not significant differences in clinical characteristics between EC patients with and without adenomyosis, with the exception for nulliparity. Clinical features seem to not underlie the better EC prognosis of patients with adenomyosis compared to patients without adenomyosis.

show abstract

“…The most commonly used classification system in EC patients is the International Federation of Gynecology and Obstetrics (FIGO) staging system, in which patients with non-metastatic cancer are stratified based on the depth of myometrial invasion, cervical stromal invasion, as well as the extent of lymph node involvement (3). However, survival of patients with the same clinical stage varies widely because this system considers the survival rate independently from other prognostic factors such as age, tumor grade, and histologic type (4,5).…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of Nomograms Predicting the Overall and the Cancer-Specific Survival in Endometrial Cancer Patients

Yuan

Dong

et al. 2020

Front. Med.

View full text Add to dashboard Cite

Background: The present study was aimed at developing nomograms estimating the overall survival (OS) and cancer-specific survival (CSS) of endometrial cancer (EC)-affected patients.Patients and Methods: We retrospectively collected 145,445 EC patients between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Independent prognostic factors were identified via univariate and multivariate Cox analyses. These risk factors were used to establish nomograms to predict 3- and 5-year OS and CSS rates. Internal and external data were used for validation. The predictive accuracy and discriminative ability were measured by using concordance index (C-index) and risk group stratification.Results: A total of 63,510 patients were collected and randomly assigned into the training cohort (n = 42,340) and the validation cohort (n = 21,170). Age at diagnosis, marital status, tumor size, histologic type, lymph node metastasis, tumor grade, and clinical stage were identified as independent prognostic factors for OS and CSS (p < 0.05 according to multivariate Cox analysis) and were further used to construct the nomograms. The area under the receiver operating characteristics (ROC) curve was greater than that of International Federation of Gynecology and Obstetrics (FIGO) staging system for predicting OS (0.83 vs. 0.73, p < 0.01) and CSS (0.87 vs. 0.79, p < 0.01) in the training cohort. The stratification into different risk groups ensured a significant distinction between survival curves within different FIGO staging categories.Conclusion: We constructed and validated nomograms that accurately predicting OS and CSS in EC patients. The nomograms can be used for estimating OS and CSS of individual patients and establishing their risk stratification.

show abstract

The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer

Cited by 16 publications

References 22 publications

EP663 Correlation between adenomyosis and endometrial cancer: 6-year experience of a single center

EP663 Correlation between adenomyosis and endometrial cancer: 6-year experience of a single center

Clinical Characteristics of Patients with Endometrial Cancer and Adenomyosis

Development and Validation of Nomograms Predicting the Overall and the Cancer-Specific Survival in Endometrial Cancer Patients

Contact Info

Product

Resources

About